Pharmaceuticals
Accord Healthcare Announces Launch of Denosumab∇ - Second Biosimilar in Bone Health
∇ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. LONDON, Dec. 2, 2025 /PRNewswire/ -- Accord Healthcare today announced the launch of Osvyrti (denosumab), a biosimilar to Prolia® (Amgen), and Jubereq (denosumab), a biosimilar to...
2025-12-02 15:00
1324
Amaran Biotech's Vaccine Adjuvant AB-801 Receives FDA Drug Master File (DMF) Filing Acknowledgement
HSINCHU, Dec. 2, 2025 /PRNewswire/ -- Amaran Biotech, a next-generation Contract Development and Manufacturing Organization (CDMO), announced that its self-developed, GMP-grade high-purity vaccine adjuvantAB-801 has received an Acknowledgement Letter from the U.S. Food and Drug Administration (FD...
2025-12-02 14:42
1114
GC Biopharma's Varicella Vaccine Strain 'MAV/06' Listed in WHO Position Paper
* Officially recognized by WHO as a standard varicella vaccine strain alongside Oka * Interchangeability endorsed, enhancing global supply security YONGIN, South Korea, Dec. 2, 2025 /PRNewswire/ -- GC Biopharma (006280.KS), a global biopharmaceutical company, today announced that its propriet...
2025-12-02 13:00
2094
Lynk Pharmaceuticals Announces FDA IND Approval of Its Allosteric TYK2 Inhibitor LNK01006
HANGZHOU, China and SHANGHAI and BOSTON, Dec. 2, 2025 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on developing innovative therapies for immune and inflammatory diseases, today ann...
2025-12-02 08:00
3384
Generate:Biomedicines to Initiate Global Phase 3 Studies of GB-0895, a Long-Acting Anti-TSLP Antibody for Severe Asthma Engineered with AI
SOLAIRIA-1 and SOLAIRIA-2 will evaluate GB-0895 in approximately 1,600 patients with severe asthma whose disease remains inadequately controlled on current therapies These are the first global Phase 3 studies of a long-acting anti-TSLP antibody, marking a pivotal step as GB-0895 advances the pro...
2025-12-01 19:00
1613
Lee's Pharm Supports Disaster Relief Efforts for Wang Fuk Court in Tai Po
HONG KONG, Dec. 1, 2025 /PRNewswire/ -- Lee's Pharmaceutical Holdings Limited (" Lee's Pharm" or the "Group", stock code: 0950.HK) expresses its deep condolences to the victims of the serious fire at Wang Fuk Court inTai Po, which caused multiple casualties and left many residents homeless and in ...
2025-12-01 18:46
1311
Hedia appoints new CEO: Rasmus Kofoed to succeed Lars Christian Lund
COPENHAGEN, Denmark, Dec. 1, 2025 /PRNewswire/ -- Danish diabetes‑tech company Hedia is implementing a leadership change effective1 December 2025, when Rasmus Kofoed will take over as Chief Executive Officer (CEO). He succeeds Lars Christian Lund, who after approximately 2 years in the role has d...
2025-12-01 16:00
1337
The Wisdom Derived from the Great Migration: Hakka Medicine - The Unique "Medical Epic" of the Hakka People
HONG KONG, Dec. 1, 2025 /PRNewswire/ -- From November 23rd to 25th, the 7th World Hakka Conference was held in Meizhou,Guangdong. With the theme "Gathering Global Hakka Businesspeople to Foster High-Quality Development," the conference adhered to the principles of "openness, innovation, cooperati...
2025-12-01 15:26
1817
Ascletis Selects Its First Oral GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development
- Utilizing Ascletis' Peptide Oral Transport ENhancement Technology (POTENT), ASC37 oral tablets achieved average absolute oral bioavailability of 4.2%, approximately 9-, 30-, and 60-fold higher than semaglutide, tirzepatide, and retatrutide in the oral SNAC formulation, respectively, in head-to...
2025-11-30 18:15
2363
BioDlink Showcases Europe-China CMC Collaboration Amid Developmental Breakthrough
* Recognized as Biologics CDMO of the Year, BioDlink shares insights into the world's first approved EGFR-targeted ADC for recurrent/metastatic nasopharyngeal carcinoma * The company enables seamless Europe–China tech transfer and faster biologics development through an integrated, end-to-end...
2025-11-28 21:00
2244
Imugene and JW Therapeutics Announce a Collaboration to Advance onCARlytics and Carteyva® Combination in Solid Tumours
* Imugene and JW Therapeutics (Shanghai) Co., LTD have entered a strategic collaboration to evaluate a novel combination therapy using Imugene's onCARlytics (CF33-CD19) oncolytic virus and JW's CD19 CAR-T cell therapy, Carteyva®, in refractory solid tumors. * The collaboration includes precli...
2025-11-28 13:00
1556
The Annals of Oncology Publishes Results of Phase II Study of Sacituzumab Tirumotecan Monotherapy for Urothelial Carcinoma
CHENGDU, China, Nov. 28, 2025 /PRNewswire/ -- Recently, Clinical study results from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", HKEX: 6990)'s TROP2 ADC sacituzumab tirumotecan (sac-TMT) monotherapy for advanced or metastatic urothelial carcinoma (UC) patients has been publ...
2025-11-28 12:32
3112
Strategic Partnership | Sanyou Bio and Korea's FatiAbGen Join Forces to Expand the Global Biopharma Market
SHANGHAI, Nov. 27, 2025 /PRNewswire/ -- Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. ("Sanyou Bio") andSouth Korea's FatiAbGen Co., Ltd. today jointly announced the signing of a comprehensive strategic collaboration agreement covering joint project development, exclusive representation in the K...
2025-11-27 22:00
2694
Once-Monthly GLP-1 RA | Gan & Lee Pharmaceuticals Initiates Phase 3 Clinical Study (GRADUAL-3) of the First Chinese Once-Monthly GLP-1 RA for Weight Management
BEIJING, Nov. 27, 2025 /PRNewswire/ -- Gan & Lee Pharmaceuticals (Gan & Lee, stock code: 603087.SH) announced the initiation of GRADUAL-3, its third large-scale phase 3 clinical study of the glucagon-like peptide-1 receptor agonist (GLP-1 RA) bofanglutide (research code: GZR18) injection in adult...
2025-11-27 16:57
1344
IASO Bio Announces BLA Approval of Fucaso (Equecabtagene Autoleucel) by the Hong Kong Department of Health for the Treatment of Relapsed or Refractory Multiple Myeloma
SHANGHAI and NANJING, China and PLEASANTON, Calif., Nov. 27, 2025 /PRNewswire/ -- IASO Biotechnology ("IASO Bio"), a commercial-stage biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of novel cell therapies and biologics for hematologic mali...
2025-11-27 13:44
1438
SK Biopharmaceuticals Expands Radiopharmaceutical Therapy Portfolio with Second In-licensed Candidate from Wisconsin Alumni Research Foundation
New addition strengthens SK Biopharmaceuticals' radiopharmaceutical therapy portfolio and reinforces its R&D capabilities through global partnerships and value chain integration SEOUL, South Korea, Nov. 26, 2025 /PRNewswire/ -- SK Biopharmaceuticals, CO., Ltd., a biotech company specializing in ...
2025-11-27 10:39
1460
Celltrion announces publication of post-hoc analysis of LIBERTY-CD study of ZYMFENTRA® (infliximab-dyyb), indicating consistent efficacy across disease location, including the terminal ileum in Clinical Gastroenterology and Hepatology journal
* Findings from the post-hoc analysis of LIBERTY-CD study indicates efficacy of ZYMFENTRA® (subcutaneous infliximab) regardless of disease location, consistent across ileum-dominant and colon-dominant Crohn's disease (CD) * Findings support the therapeutic potential of ZYMFENTRA in addressing ...
2025-11-26 14:48
2993
Renalys Pharma Announces Positive Topline Results from Phase III Study of Sparsentan in Japanese Patients with IgA Nephropathy
– In a Phase 3 clinical study evaluating the efficacy and safety of sparsentan in Japanese patients with IgA nephropathy (N=35), the percent change from baseline in the 24-hour urine protein-to-creatinine ratio at Week 36, which was the study's primary endpoint, was -58.54%. Sparsentan was well-t...
2025-11-26 14:00
1262
Prestige Biopharma and Biosidus Enter Exclusive License Agreement for Tuznue® Commercialization in Latin America
SINGAPORE, Nov. 26, 2025 /PRNewswire/ -- Prestige Biopharma, a biopharmaceutical company specializing in antibody therapeutics, today announced an exclusive license and supply agreement with Biosidus, a biotechnology company headquartered inBuenos Aires, Argentina, with decades of experience in ...
2025-11-26 09:06
1686
Innova Therapeutics to Advance Novel Cancer Treatment with Enci Therapeutics Acquisition
The acquisition of Enci Therapeutics will advance Innova Therapeutics' lead program, IVT-8086, a humanized monoclonal antibody targeting SFRP2 which is expressed in most solid and hematological cancers. IVT-8086 is the only cancer therapeutic that targets multiple cell types associated with canc...
2025-11-25 23:06
1058
Week's Top Stories
Most Reposted
MTR Lab and ZGC Science City Ltd Establish Ecosystem Partnership
[Picked up by 310 media titles]
2026-03-18 12:00
Visa Working Capital Index: Asia Pacific CFOs Call for Flexible, Digital Finance Solutions
[Picked up by 308 media titles]
2026-03-24 14:00HOY Unveils a Powerhouse Line-up of Talent for its Bold New Chapter
[Picked up by 305 media titles]
2026-03-20 09:36
Beijing InfoComm China 2026 Conference Lineup Presents Future of AI in Tech Aligning with the Nation's Next Strategic Five-Year Plan
[Picked up by 298 media titles]
2026-03-18 08:00
MetaOptics progresses on its strategic growth and leadership transition initiatives
[Picked up by 283 media titles]
2026-03-20 08:15Most Read
H World Group Reports Strong Full-Year 2025 Results, Driven by Asset-light Growth
2026-03-18 21:05
7457
Everbright Environment Announces 2025 Annual Results
2026-03-20 23:14
7272
Ten Pao Group Announces 2025 Annual Results
2026-03-20 23:35
7108
FiEE, Inc. Announces Fourth Quarter and Full-Year 2025 Financial Results
2026-03-21 04:05
7027